This article needs additional citations for verification. (April 2013)
|AHFS/Drugs.com||Consumer Drug Information|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||383.40 g·mol−1|
Ceftizoxime is a third-generation cephalosporin available for parenteral administration. Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.
- Aldridge KE (1990). "An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria". Clinical Therapeutics. 12 Suppl C: 3–12. PMID 2202509.
- DE 2810922, Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "New cepham compounds and processes for the production thereof", issued 29 August 1985, assigned to Fujisawa
- US 4427674, Takaya T, Hisashi T, Kiyoshi T, Toshiyuki C, "Cephem compounds", issued 24 January 1984, assigned to Fujisawa